Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression.
|
30134951 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bidirectional Cause-Effect Relationship Between Urinary Interleukin-6 and Mood, Irritation, and Mental Activity in a Breast Cancer Survivor.
|
30546293 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, this work demonstrates that breast cancer-derived exosomes are capable of inducing IL-6 secretion and a pro-survival phenotype in macrophages, partially <i>via</i> gp130/STAT3 signaling.
|
29867925 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling.
|
29388151 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer cells grown as spheroids are uniquely receptive to IL-6-dependent induction of hepcidin by tumor-associated fibroblasts, since IL-6 does not induce hepcidin in cells grown as monolayers.
|
29695834 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.
|
29027990 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The supervised exercise training did not counteract this increase in inflammation, suggesting that beneficial effects of exercise on fatigue during adjuvant chemotherapy for breast cancer are not essentially mediated by IL-6, IL-1ra, or the IL-6/IL-1ra ratio.
|
29235043 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies.
|
30467123 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of IL-6/IL-10 was associated with clinicopathological criteria (e.g. hormone receptor status, all P < 0.05), improved disease-free survival (DFS; P < 0.05) and improved BC-specific survival (BCSS; only IL-6, P = 0.017).
|
29256156 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast tumor interleukin-6 (IL-6) level increases with tumor grade, and elevated serum IL-6 correlates with poor survival in patients with breast cancer.
|
29715108 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response.
|
30332900 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that IL-6 secreted by adipocytes induce EMT in breast cancer cells.
|
29891854 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the IL-6/STAT3 signaling pathway might be a promising candidate target in developing novel therapeutic strategies to eliminate e-MDSCs and improve breast cancer prognosis.
|
30083161 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our aim is to present a brief knowledge of IL-6's role in breast cancer.
|
29413760 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanistically, adipocyte-derived interleukin-6 (IL-6) and leptin may facilitate PLOD2 upregulation in breast cancer cells and promote breast cancer metastasis in tail vein metastasis assays.
|
30563531 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we showed that GRAMD1B expression is upregulated on IL-6 but downregulated upon treatment with the JAK2 inhibitor AG490 in the breast cancer MDA-MB-231 cells.
|
29934528 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, elevation of MAO-A with 5-azacytidine (5-Aza) modulated IL-6 mediated angiogenesis and invasive signatures including VEGF, MMPs and EMT in hypoxic breast cancer.
|
29695771 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the isolated compounds, 2 and 5 showed significant inhibitory activities toward the LPS-induced production of IL-6 in the human acute monocytic leukemia cell line THP-1, and 7 displayed cytotoxicity against MCF-7, PC9, A549, and breast cancer stem cells (MCF-7-Oct4-GFP) with IC<sub>50</sub> values of 5.2, 5.6, 7.8, and 10 μM, respectively.
|
29648818 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer.
|
29844821 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both the CC chemokine ligand 5 (CCL5/RANTES) and interleukin-6 (IL-6), released by mesenchymal stem cells (MSCs) as well as by neoplastic cells, promote breast cancer cell progression through autocrine and paracrine mechanisms.
|
29707128 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Total metabolic rate, physical activity level, mean MET and steps, fatigue, self-perceived cognitive functioning , and biomarkers (C-reactive protein [CRP], interleukin 6, macrophage migration inhibiting factor [MIF], tumor necrosis factor [TNF]-α, brain-derived neurotrophic factor [BDNF], insulin-like growth factor 1 [IGF1]) were assessed in 60 patients with breast cancer in the aftercare phase before ( t<sub>0</sub>) and 8 months after ( t<sub>1</sub>) the intervention.
|
28617135 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the roles of serum interleukin-6 (IL-6), IL-8, IL-10, squamous cell cancer antigen (SCC-Ag), and cytokeratin 21-1 fragment (CYFRA 21-1) in the metastasis and prognosis of breast cancer.A total of 534 breast cancer patients admitted to our department between January 2011 and December 2014 were enrolled in this study.
|
29245248 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy.
|
28025102 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that it may be possible for Evista to emerge as a chemoprevention agent for breast cancer and other cancers such as colon cancer or multiple myeoloma by targeting IL-6/STAT3 signaling.
|
28711499 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 <i>Trans</i>-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells <i>via</i> Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.
|
29326716 |
2017 |